BioNTech Broadens Management Board by Appointing Jens Holstein as CFO
18 Mayo 2021 - 05:00AM
MAINZ, Germany, May 18, 2021
— BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”),
announced today that the Supervisory Board has appointed Jens
Holstein to the Management Board as Chief Financial Officer (CFO).
As of July 1, 2021, Jens Holstein will join the Management Board to
help strengthen BioNTech on its growth trajectory as a global,
fully integrated immunotherapy company with an approved or
authorized product. He previously served as CFO for MorphoSys AG
and in various CFO and general management roles within the
Fresenius SE Group. Jens Holstein takes over the CFO role from Dr.
Sierk Poetting who will fully focus on his tasks as Chief Operating
Officer (COO) going forward.
Under Sierk Poetting’s leadership, BioNTech grew
from approximately 300 employees when he joined the company in
2014, to more than 2,000 employees to date. In his position as CFO,
Sierk has played a fundamental role in BioNTech’s successful IPO in
October 2019 as the eighth German company to be listed on Nasdaq.
Over the past months, Sierk’s and his teams’ efforts have been
crucial to the expansion of BioNTech’s manufacturing partner
network to meet the global demand of the Company’s COVID-19
vaccine, including the Marburg site, which is one of the largest
mRNA manufacturing facilities worldwide. In his role as COO, he
will drive the further development and execution of a digital
strategy, which is comprised of the automation of R&D and
production and the further expansion of BioNTech’s global
manufacturing footprint, including the recently announced site in
Singapore.
“The success of BioNTech’s COVID-19 vaccine
development program ‘Project Lightspeed’ has led to the accelerated
transformation to a global immunotherapy company which requires
extensive manufacturing capacities to support worldwide supply. The
extension of the Management Board allows Sierk to further focus on
manufacturing as well as the digital transformation of BioNTech,”
said Helmut Jeggle, Chairman of the
BioNTech Supervisory Board. “We are looking forward to
Jens Holstein joining the Management Board. He has extensive
international business and financial leadership experience of more
than 25 years in the pharmaceutical industry. Jens is an excellent
addition to drive BioNTech’s next phase of growth and jointly
foster the foundation for long-term, global success.”
“Through the development of a well-tolerated and
effective COVID-19 vaccine, BioNTech has achieved a historic
breakthrough for science. This first product authorized for use
marked a crucial milestone in the Company’s growth path. I am
thrilled to join the Management Board at this exciting time in the
Company’s development,” said Jens Holstein. “With
the proceeds from the COVID-19 vaccine, BioNTech will be in a
position to accelerate its research pipeline in cancer therapies,
infectious diseases, regenerative therapies, inflammatory
reactions, as well as autoimmune diseases. I’m looking forward to
supporting this outstanding team in fulfilling its mission of
improving the health of people worldwide.”
As CFO, Jens will work closely with the other
Management Board members to drive BioNTech’s financial performance.
He will be responsible for Finance, Tax, Treasury, Human Resources
and Purchasing. In addition, Jens will play a leadership role in
the development and execution of the Company’s regional expansion
plans.
Prior to joining BioNTech, Jens was CFO of
dual-listed MorphoSys AG where he was instrumental in building a
fully integrated biopharmaceutical company. Before joining
MorphoSys in 2011, Jens served in multiple CFO positions as well as
general management roles within the Fresenius SE Group. He served
as Regional CFO for the region EME (Europe/Middle East) and as
Managing Director of Fresenius Kabi Deutschland GmbH. From 2006 to
2010, he was Regional Chief Financial Officer of Fresenius Kabi
Asia Pacific Ltd., based in Hong Kong. Prior to this appointment,
Jens Holstein was Managing Director of Fresenius ProServe GmbH, and
CFO and Labor Director of the company's subsidiary Wittgensteiner
Kliniken AG. Earlier positions within Fresenius included General
Manager of hospitalia care GmbH, Commercial Manager of the Projects
& Service business unit of Fresenius AG and Commercial Manager
of hospitalia international GmbH. Jens Holstein also spent several
years in the consulting industry, including in M&A with
positions in Frankfurt and London. Jens Holstein holds a Diploma in
Business Administration from the University of Münster, Germany. He
is also a Non-Executive Member of the Board of Directors at global
genomic diagnostics company Veracyte Inc.
About BioNTechBiopharmaceutical
New Technologies is a next generation immunotherapy company
pioneering novel therapies for cancer and other serious diseases.
The Company exploits a wide array of computational discovery and
therapeutic drug platforms for the rapid development of novel
biopharmaceuticals. Its broad portfolio of oncology product
candidates includes individualized and off-the-shelf mRNA-based
therapies, innovative chimeric antigen receptor T cells, bispecific
checkpoint immuno-modulators, targeted cancer antibodies and small
molecules. Based on its deep expertise in mRNA vaccine development
and in-house manufacturing capabilities, BioNTech and its
collaborators are developing multiple mRNA vaccine candidates for a
range of infectious diseases alongside its diverse oncology
pipeline. BioNTech has established a broad set of relationships
with multiple global pharmaceutical collaborators, including
Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the
Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
For more information, please visit
www.BioNTech.de
Forward-Looking StatementsThis
press release contains “forward-looking statements” of BioNTech
within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements may include, but may not
be limited to, statements concerning: BioNTech’s efforts to combat
COVID-19; the ability of BioNTech to supply the quantities of
BNT162 to support clinical development and market demand, including
our production estimates for 2021; and the potential benefits of
BioNTech’s leadership hires. Any forward-looking statements in this
press release are based on BioNTech’s current expectations and
beliefs of future events. The forward-looking statements in this
press release are neither promises nor guarantees, and you should
not place undue reliance on these forward-looking statements
because they involve known and unknown risks, uncertainties, and
other factors, many of which are beyond BioNTech’s control and
which could cause actual results to differ materially from those
expressed or implied by these forward-looking statements. You
should review the risks and uncertainties described under the
heading “Risk Factors” in BioNTech’s Annual Report on Form 20-F for
the Year Ended December 31, 2020, filed with the SEC on March 30,
2021, which is available on the SEC’s website at www.sec.gov. All
information in this press release is as of the date of the release,
and BioNTech undertakes no duty to update this information unless
required by law.
Media RelationsJasmina Alatovic+49 (0)6131 9084
1513 Media@biontech.de
Investor RelationsSylke Maas, Ph.D. +49 (0)6131
9084 1074 Investors@biontech.de
BioNTech (NASDAQ:BNTX)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
BioNTech (NASDAQ:BNTX)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024